Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKesson
Boehringer Ingelheim
Merck
Harvard Business School

Last Updated: January 19, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Alisertib


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Alisertib?

Alisertib is an investigational drug.

There have been 57 clinical trials for Alisertib. The most recent clinical trial was a Phase 3 trial, which was initiated on June 11th 2012.

The most common disease conditions in clinical trials are Lymphoma, Neoplasms, and Adenocarcinoma. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., National Cancer Institute (NCI), and M.D. Anderson Cancer Center.

There are two hundred and nineteen US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Alisertib
TitleSponsorPhase
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerNational Cancer Institute (NCI)Phase 1/Phase 2
Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell CancerM.D. Anderson Cancer CenterPhase 1/Phase 2
Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung CancerNational Cancer Institute (NCI)Phase 1

See all Alisertib clinical trials

Clinical Trial Summary for Alisertib

Top disease conditions for Alisertib
Top clinical trial sponsors for Alisertib

See all Alisertib clinical trials

US Patents for Alisertib

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Alisertib ⤷  Try it Free Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Try it Free
Alisertib ⤷  Try it Free Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH (Darmstadt, DE) ⤷  Try it Free
Alisertib ⤷  Try it Free Aurora A kinase inhibitor Eli Lilly and Company (Indianapolis, IN) ⤷  Try it Free
Alisertib ⤷  Try it Free Use of inhibitors of Bruton's tyrosine kinase (Btk) Pharmacyclics LLC (Sunnyvale, CA) ⤷  Try it Free
Alisertib ⤷  Try it Free .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof Quadriga Biosciences, Inc. (Los Altos, CA) ⤷  Try it Free
Alisertib ⤷  Try it Free Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate Millennium Pharmaceuticals, Inc. (Cambridge, MA) ⤷  Try it Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Alisertib

Drugname Country Document Number Estimated Expiration Related US Patent
Alisertib Australia AU2011261185 2030-06-03 ⤷  Try it Free
Alisertib Australia AU2015275321 2030-06-03 ⤷  Try it Free
Alisertib Australia AU2018204179 2030-06-03 ⤷  Try it Free
Alisertib Australia AU2020202752 2030-06-03 ⤷  Try it Free
Alisertib Brazil BR112012030625 2030-06-03 ⤷  Try it Free
Alisertib Canada CA2800913 2030-06-03 ⤷  Try it Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Baxter
McKesson
Boehringer Ingelheim
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.